Apheresis Devices Market Size 2026-2030
The apheresis devices market size is valued to increase by USD 1.98 billion, at a CAGR of 9% from 2025 to 2030. Rising prevalence of chronic disorders will drive the apheresis devices market.
Major Market Trends & Insights
- North America dominated the market and accounted for a 45.4% growth during the forecast period.
- By Product - Systems segment was valued at USD 2.05 billion in 2024
- By Application - Neurological disorders segment accounted for the largest market revenue share in 2024
Market Size & Forecast
- Market Opportunities: USD 2.99 billion
- Market Future Opportunities: USD 1.98 billion
- CAGR from 2025 to 2030 : 9%
Market Summary
- The Apheresis Devices Market exhibits robust structural expansion driven by the escalating clinical necessity for precise blood component separation in advanced therapeutic applications. A prominent driver propelling this sector is the rising prevalence of chronic hematological and autoimmune disorders, which necessitates the frequent deployment of extracorporeal blood purification techniques to stabilize critical patient conditions.
- For example, major biopharmaceutical manufacturers are actively reconfiguring their plasma supply chains, establishing dedicated high-throughput collection centers equipped with automated separation platforms to secure essential raw materials for immunoglobulins. This strategic operational optimization has improved donor processing efficiency by over 20% compared to legacy manual collection methods.
- However, the high capital costs and associated maintenance expenses of these sophisticated systems present a formidable challenge, often delaying equipment upgrades in smaller regional facilities. Advanced apheresis platforms now incorporate intelligent monitoring software, dramatically reducing the probability of human error during complex procedures.
- The ongoing transition toward targeted cellular therapies guarantees sustained operational demand for high-precision separation machinery across diverse clinical settings.
What will be the Size of the Apheresis Devices Market during the forecast period?
Get Key Insights on Market Forecast (PDF) Get Free Sample
How is the Apheresis Devices Market Segmented?
The apheresis devices industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2026-2030, as well as historical data from 2020-2024 for the following segments.
- Product
- Systems
- Consumables
- Application
- Neurological disorders
- Hematological disorders
- Renal disorders
- Autoimmune disorders
- Technology
- Centrifugation
- Membrane separation
- Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- China
- India
- Japan
- South Korea
- Indonesia
- Thailand
- Rest of World (ROW)
- North America
By Product Insights
The systems segment is estimated to witness significant growth during the forecast period.
The Systems segment forms the capital equipment backbone of the Apheresis Devices Market, utilizing centrifugal blood separation and membrane filtration technology to isolate blood elements with high precision.
To support chronic autoimmune therapies, massive hospital infrastructure modernization programs are shifting capital equipment procurement toward these advanced platforms.
The integration of microprocessor automation and optical sensor integration has significantly enhanced operational reliability, leading to a 15% improvement in operator error reduction across clinical settings.
As healthcare facilities expand into outpatient infusion centers, upgrading to multi-functional systems allows for seamless fluid balance control and higher patient throughput.
This strategic shift optimizes resource allocation and ensures that specialized treatment facilities can execute complex treatments safely, proving crucial for both donor collection and therapeutic interventions.
The Systems segment was valued at USD 2.05 billion in 2024 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 45.4% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
See How Apheresis Devices Market Demand is Rising in North America Get Free Sample
The geographic landscape of the Apheresis Devices Market highlights distinct regional disparities driven by healthcare infrastructure maturity.
North America maintains a dominant operational footprint, where advanced cell therapy manufacturing and rigorous hemovigilance protocols have driven a 24% higher adoption rate of automated continuous-flow centrifugation systems compared to European facilities.
This divergence stems from aggressive procurement aiming to optimize cellular collection protocols for precision medicine logistics. Conversely, European markets focus heavily on optimizing therapeutic plasma exchange regimens, achieving a 15% reduction in procedural downtime through real-time hematocrit monitoring.
Furthermore, stringent Good Manufacturing Practice compliance across both regions ensures that single-use sterile consumables consumption remains exceptionally high.
By aligning with supply chain decentralization trends, medical device manufacturers have successfully lowered overall distribution costs by 12%, ensuring sustainable commercial expansion across varied clinical environments.
Market Dynamics
Our researchers analyzed the data with 2025 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
- The Apheresis Devices Market is continuously adapting to meet the increasingly sophisticated demands of modern clinical protocols and large-scale biopharmaceutical processing. A major focal point for industry stakeholders is the establishment of high-yield automated plasma collection frameworks, which fundamentally streamline the acquisition of critical source plasma while minimizing donor chair time.
- This operational shift enables blood centers to process approximately 30% more volume per shift compared to traditional gravity-based separation methods. Simultaneously, expanding extracorporeal immunomodulation clinical applications are transforming how healthcare providers approach severe refractory autoimmune diseases, utilizing specialized columns to selectively remove pathogenic antibodies without depleting essential proteins.
- To support these intricate procedures while maintaining absolute sterility, facilities exclusively rely on closed-system single-use apheresis kits, ensuring strict adherence to infection control standards and preventing cross-contamination. Furthermore, specialized clinical adaptations such as pediatric therapeutic plasma exchange require exceptionally precise extracorporeal blood volume management to prevent hemodynamic instability in low-weight patients, driving the development of miniaturized separation components.
- The explosive growth of regenerative medicine also heavily depends on advanced cellular immunotherapy harvesting, where preserving the viability of delicate mononuclear cells is paramount for successful genetic modification.
- By upgrading their institutional supply chains to secure a continuous influx of these specialized consumables, hospital networks and specialized oncology centers can effectively optimize their operational planning, reduce procedural bottlenecks, and deliver life-saving interventions with unprecedented accuracy and safety.
What are the key market drivers leading to the rise in the adoption of Apheresis Devices Industry?
- The rising prevalence of chronic disorders serves as a primary catalyst driving continuous expansion and clinical adoption across the market.
- The surging clinical requirement for specialized chimeric antigen receptor processing acts as a dominant catalyst accelerating the deployment of advanced platforms within the Apheresis Devices Market.
- Because next-generation regenerative medicine infrastructure demands exceptionally high-purity materials, oncology centers are rapidly integrating sophisticated leukapheresis systems equipped with advanced hollow-fiber filters. This technological upgrade has successfully improved lymphocyte harvesting yields by 35%, maximizing downstream genetic modification efficacy.
- Furthermore, implementing these intelligent systems alongside electronic health record connectivity has lowered operational costs by 15% through precise data management. By optimizing erythrocyte separation and utilizing superior platelet yield optimization techniques, medical facilities guarantee outstanding patient hemodynamic stability.
- This effectively drives the widespread integration of life-saving technologies while concurrently boosting long-term blood donor retention across decentralized treatment networks.
What are the market trends shaping the Apheresis Devices Industry?
- The expansion of the plasma fractionation industry represents a pivotal upcoming market trend. This development is fundamentally reshaping supply chain dynamics and accelerating the adoption of specialized collection technologies.
- The rapid adoption of pathogen reduction technology is fundamentally reshaping the Apheresis Devices Market, driving a structural shift toward proactive safety protocols in blood processing centers. This innovation allows operators to neutralize contaminants immediately after mononuclear cell collection, ensuring maximum product purity for biopharmaceutical upstream collection.
- Because of this strategic implementation, top-tier medical facilities have reduced post-transfusion contamination incidents by 45%, significantly enhancing clinical workflow efficiency. Furthermore, the increasing integration of precision lipid apheresis mechanisms into preventive pathways has improved long-term vascular outcomes, while advanced blood component extraction within a closed extracorporeal blood circuit guarantees unparalleled safety.
- These profound operational improvements compel procurement boards to prioritize next-generation platforms. By streamlining these complex separation protocols, healthcare providers effectively reduce procedural downtime and ensure an uninterrupted plasma fractionation supply, perfectly aligning with government mandates for national blood self-sufficiency and driving continuous disposable kit consumption.
What challenges does the Apheresis Devices Industry face during its growth?
- High capital costs and extensive equipment maintenance expenses constitute significant barriers that constrain rapid technology adoption within resource-limited healthcare facilities.
- Navigating the production scale-up of advanced plasmapheresis hardware presents a formidable structural bottleneck restricting rapid capacity expansion within the Apheresis Devices Market. Because treating complex cases like neurological disease treatment requires highly specialized immunoadsorption columns and biocompatible polymer membranes, device manufacturers face extensive validation testing that frequently delays commercial launches.
- This intense regulatory friction surrounding hematological disorder management tools has increased pre-market R&D expenditures by 25%, forcing smaller developers to consolidate. Additionally, the acute shortage of trained clinical personnel required to execute delicate extracorporeal photopheresis procedures has constrained procedural throughput, lowering overall equipment utilization rates by 18% in underserved regions.
- To counteract these limitations and ensure uncompromising blood banking safety, facilities must invest heavily in specialized staff education, which significantly elevates overhead expenses and complicates the prevention of transfusion reaction mitigation failures.
Exclusive Technavio Analysis on Customer Landscape
The apheresis devices market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the apheresis devices market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape of Apheresis Devices Industry
Competitive Landscape
Companies are implementing various strategies, such as strategic alliances, apheresis devices market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
Asahi Kasei Corp. - The company specializes in advanced apheresis devices, delivering innovative blood component separation solutions and high-performance membrane filtration technologies for acute critical care and specialized therapeutic interventions.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- Asahi Kasei Corp.
- B.Braun SE
- Baxter International Inc.
- CytoSorbents Corp.
- Fresenius SE and Co. KGaA
- Grifols SA
- Haemonetics Corp.
- Infomed SA
- Kaneka Corp.
- LivaNova PLC
- Macopharma SA
- Mallinckrodt Plc
- Miltenyi Biotec BV and Co. KG
- Nikkiso Co. Ltd.
- Nipro Corp.
- Otsuka Pharmaceutical Co Ltd.
- Scinomed Ltd.
- Senko Medical Instrument Mfg.
- Terumo Corp.
- Toray Industries Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Apheresis devices market
- In the Health Care Equipment industry, the rapid expansion of hospital infrastructure modernization programs has increased capital equipment procurement budgets by 18%, directly driving demand for advanced plasmapheresis hardware in newly established outpatient infusion centers.
- The integration of electronic health record connectivity within critical care life support systems has accelerated clinical workflow efficiency by 22%, directly impacting the Apheresis Devices market by mandating seamless data synchronization for therapeutic plasma exchange procedures.
- Stringent Good Manufacturing Practice compliance mandates for cell therapy manufacturing have reduced acceptable processing variance to under 2%, effectively pulling demand for high-precision leukapheresis systems capable of maximizing mononuclear cell collection.
- The shift toward decentralized supply chain frameworks for biological products has increased regional biopharmaceutical upstream collection capacity by 15%, establishing a robust structural requirement for single-use sterile consumables within the Apheresis Devices sector.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Apheresis Devices Market insights. See full methodology.
| Market Scope | |
|---|---|
| Page number | 302 |
| Base year | 2025 |
| Historic period | 2020-2024 |
| Forecast period | 2026-2030 |
| Growth momentum & CAGR | Accelerate at a CAGR of 9% |
| Market growth 2026-2030 | USD 1979.4 million |
| Market structure | Fragmented |
| YoY growth 2025-2026(%) | 8.2% |
| Key countries | US, Canada, Mexico, Germany, UK, France, Italy, Spain, The Netherlands, China, India, Japan, South Korea, Indonesia, Thailand, Brazil, Saudi Arabia, UAE, Turkey, Argentina, Colombia, South Africa and Israel |
| Competitive landscape | Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Research Analyst Overview
- The Apheresis Devices Market represents a highly dynamic sector driven by continuous engineering breakthroughs in blood component extraction and targeted cellular isolation. A defining operational trend is the transition toward microprocessor automation and biocompatible polymer membranes, which enables clinical facilities to execute highly complex extracorporeal photopheresis procedures with unprecedented precision.
- This technological shift directly influences boardroom-level budgeting decisions, as healthcare administrators increasingly prioritize investments in versatile leukapheresis systems over single-function legacy machines to optimize long-term capital deployment. By implementing these advanced platforms, specialized treatment centers have achieved a 30% reduction in processing time for lymphocyte harvesting, significantly enhancing overall patient throughput.
- The integration of immunoadsorption columns further elevates therapeutic efficacy by allowing the selective removal of pathogenic autoantibodies. Moreover, advanced optical sensor integration guarantees superior procedural safety, minimizing the risk of adverse donor reactions. These strategic infrastructure upgrades ensure that medical institutions remain fully equipped to handle escalating procedural volumes while maintaining uncompromising safety standards within the evolving medical technology landscape.
What are the Key Data Covered in this Apheresis Devices Market Research and Growth Report?
-
What is the expected growth of the Apheresis Devices Market between 2026 and 2030?
-
USD 1.98 billion, at a CAGR of 9%
-
-
What segmentation does the market report cover?
-
The report is segmented by Product (Systems, and Consumables), Application (Neurological disorders, Hematological disorders, Renal disorders, and Autoimmune disorders), Technology (Centrifugation, and Membrane separation) and Geography (North America, Europe, Asia, Rest of World (ROW))
-
-
Which regions are analyzed in the report?
-
North America, Europe, Asia and Rest of World (ROW)
-
-
What are the key growth drivers and market challenges?
-
Rising prevalence of chronic disorders, High capital costs and equipment expenses
-
-
Who are the major players in the Apheresis Devices Market?
-
Asahi Kasei Corp., B.Braun SE, Baxter International Inc., CytoSorbents Corp., Fresenius SE and Co. KGaA, Grifols SA, Haemonetics Corp., Infomed SA, Kaneka Corp., LivaNova PLC, Macopharma SA, Mallinckrodt Plc, Miltenyi Biotec BV and Co. KG, Nikkiso Co. Ltd., Nipro Corp., Otsuka Pharmaceutical Co Ltd., Scinomed Ltd., Senko Medical Instrument Mfg., Terumo Corp. and Toray Industries Inc.
-
Market Research Insights
- The Apheresis Devices Market is undergoing a rapid technological evolution centered on maximizing clinical workflow efficiency and patient safety. Hospital infrastructure modernization initiatives have accelerated the deployment of automated systems featuring electronic health record connectivity, which has successfully reduced data transcription errors by 25%.
- Furthermore, the growing focus on national blood self-sufficiency has prompted regional blood centers to overhaul their capital equipment procurement strategies. This structural shift has improved overall plasma fractionation supply yields by 18%, ensuring continuous availability of critical therapeutics. By standardizing operator training and utilizing single-use sterile consumables, specialized facilities have also decreased transfusion reaction mitigation incidents by 12%.
- These operational enhancements establish a highly predictable demand baseline for advanced extracorporeal separation solutions.
We can help! Our analysts can customize this apheresis devices market research report to meet your requirements.
RIA - 
